Status:

RECRUITING

Adjustable Continence Therapy (ACT) for the Treatment of Female SUI

Lead Sponsor:

Uromedica

Conditions:

Urinary Incontinence

Urinary Incontinence,Stress

Eligibility:

FEMALE

22+ years

Phase:

NA

Brief Summary

A prospective, single arm, non-randomized, multicenter, prospective case-series trial. The purpose of this trial is to demonstrate the safety and effectiveness of using the Adjustable Continence Thera...

Eligibility Criteria

Inclusion Criteria:

  1. Female at least 22 years old
  2. Diagnosed with stress urinary incontinence with primary Intrinsic Sphincter Deficiency
  3. Provocative pad weight of greater than 11.0 grams
  4. Candidate for surgical intervention
  5. Negative urinalysis
  6. Normal cystourethroscopy
  7. Failed at least 6 months of previous treatment(s) for stress urinary incontinence (e.g., exercise regimen, electrical stimulation, surgical procedures, etc). Note: patients may have failed prior anti-incontinence procedures for SUI (e.g., suspension, sling, or urethral bulking agent)
  8. Willing and able to sign informed consent and comply with trial follow-up requirements

Exclusion Criteria:

  1. Pregnant or lactating
  2. Life expectancy of less than 5 years
  3. Has uncontrolled diabetes as evidenced by HbA1c over 6.5% and fasting plasma glucose over 130 mg/dL
  4. Has auto-immune disease
  5. Undergoing radiation therapy
  6. Active urinary tract infection
  7. Detrusor instability refractory to medication
  8. Reduced bladder compliance as defined by a cystometrogram
  9. Significant residual volume (greater than 100 ml) after voiding in which detrusor contraction is weak, when the bladder volume is greater than or equal to 250 ml
  10. Has, had, or is suspected of having bladder cancer
  11. History of bladder stones
  12. Urethral stricture evidenced during cystourethroscopy
  13. Has a neurogenic bladder that is atonic or has detrusor sphincter dyssynergia
  14. Has a diathesis, hemophilia, or a bleeding disorder
  15. Has a rectocele, cystocele, urethrocele, enterocele, or pelvic prolapse of grade 3 or higher
  16. Had prior pelvic radiotherapy
  17. Had a prior artificial urinary sphincter implanted
  18. Has a neurogenic condition known to affect bladder/sphincter function

Key Trial Info

Start Date :

January 26 2021

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 30 2025

Estimated Enrollment :

167 Patients enrolled

Trial Details

Trial ID

NCT04248283

Start Date

January 26 2021

End Date

December 30 2025

Last Update

July 23 2024

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

University of Colorado

Denver, Colorado, United States, 80045

2

CHI Health Research Center

Omaha, Nebraska, United States, 68124